Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results

Shinya Rai,¹ Won Seog Kim,² Kiyoshi Ando,³ Ilseung Choi,⁴ Koji Izutsu,⁵ Norifumi Tsukamoto,⁶ Masahiro Yokoyama,⁷ Kunihiro Tsukasaki,⁸ Junya Kuroda,⁹ Jun Ando,¹⁰ Michihiro Hidaka,¹¹ Youngil Koh,¹² Hirohiko Shibayama,¹³ Toshiki Uchida,¹⁴ Deok Hwan Yang,¹⁵ Kenji Ishitsuka,¹⁶ Kenichi Ishizawa,¹⁷ Jin Seok Kim,¹⁸ Hong Ghi Lee,¹⁹ Hironobu Minami,²⁰ Hyeon Seok Eom,²¹ Mitsutoshi Kurosawa,²² Jae Hoon Lee,²³ Jong Seok Lee,²⁴ Won Sik Lee,²⁵ Hirokazu Nagai,²⁶ Takero Shindo,²⁷ Dok Hyun Yoon,²⁸ Shinichiro Yoshida,²⁹ Mireille Gillings,³⁰ Hiroshi Onogi³¹ and Kensei Tobinai⁵

¹Kindai University Hospital, Osaka-Sayama, Japan; ²Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea; ³Tokai University Hospital, Isehara, Japan; ⁴National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; ⁵National Cancer Center Hospital, Tokyo, Japan; ⁶Gunma University Hospital, Maebashi, Japan; ⁷The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; ⁸International Medical Center, Saitama Medical University, Saitama, Japan; ⁹Kyoto Prefectural University of Medicine, Kyoto, Japan; ¹⁰Juntendo University Hospital, Tokyo, Japan; ¹¹National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan; ¹²Seoul National University Hospital, Seoul, Korea; ¹³Osaka University Hospital, Suita, Japan; ¹⁴Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan; ¹⁵Chonnam National University Hwasun Hospital, Jeollanam, Korea; ¹⁶Kagoshima University Hospital, Kagoshima, Japan; ¹⁷Yamagata University Hospital, Yamagata, Japan; ¹⁸Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; ¹⁹Konkuk University Medical Center, Seoul, Korea; ²⁰Kobe University Graduate School of Medicine and Hospital, Kobe, Japan; ²¹National Cancer Center, Gyeonggi, Korea; ²²National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; ²³Gachon University Gil Medical Center, Incheon, Korea; ²⁴Seoul National University Bundang Hospital, Gyeonggi, Korea; ²⁵Inje University Busan Paik Hospital, Busan, Korea; ²⁶National Hospital Organization Nagoya Medical Center, Nagoya, Japan; ²⁷Kyoto University Hospital, Kyoto, Japan; ²⁸Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; ²⁹National Hospital Organization Nagasaki Medical Center, Omura, Japan; ³⁰HUYABIO International, San Diego, CA, USA and ³¹Huya Japan GK, Tokyo, Japan

Correspondence: S. Rai rai@med.kindai.ac.jp

Received:
Accepted:
Early view:

March 25, 2022. September 27, 2022. October 6, 2022.

https://doi.org/10.3324/haematol.2022.280996

©2023 Ferrata Storti Foundation Published under a CC BY-NC license 座 0 S

Supplemental Appendix

Supplemental Protocol Synopsis

Title of Study: A Phase 2b Open-Label Single Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Protocol No: HBI-8000-203 Study site(s): 25 to 35 sites in Japan and 10 to 15 sites in South Korea Study duration: Approximately 60 months Phase: 2b Planned study period: 4quarter 2016 (first patient in) to 3quarter 2018 (last patient in) 4quarter 2021 study completion Phase: 2b Objectives: Primary: • To determine the efficacy of HBI-8000 administered twice a week (BIW) continuously Secondary: • To evaluate the safety and tolerability of HBI-8000 administered BIW continuously Endpoints: Primary: • Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: • Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: • Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: • Olderah duration of progression-free survival (PFS) • Median duration of overall survival (OS) • Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, effica and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC HBI-8000 will be administered orally approximately 30 m	Study Drug: HBI-8000						
Safety of Oral HBI-8000 in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Protocol No: HBI-8000-203 Study site(s): 25 to 35 sites in Japan and 10 to 15 sites in South Korea Study duration: Approximately 60 months Phase: 2b Planned study period: 4quarter 2016 (first patient in) to 3quarter 2018 (last patient in) 4quarter 2021 study completion Phase: 2b Objectives: Primary: • • To determine the efficacy of HBI-8000 administered twice a week (BIW) continuously Secondary: • To evaluate the safety and tolerability of HBI-8000 administered BIW continuously Endpoints: Primary: • Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: • ORR by disease subtype (see inclusion criteria) • Median duration of progression-free survival (PFS) • Median duration of response (DOR) • Safety Exploratory: • Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, effica and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC HBI-8000 will be administered orally approximately 30 minutes after any regular meal. T treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days sole for the purpose to schedule assessments required by the study.							
Peripheral T-cell Lymphoma (PTCL) Protocol No: HBI-8000-203 Study site(s): 25 to 35 sites in Japan and 10 to 15 sites in South Korea Study duration: Approximately 60 months Phase: 2b Planned study period: 4quarter 2016 (first patient in) to 3quarter 2018 (last patient in) 4quarter 2021 study completion Phase: 2b Objectives: Primary: • • To determine the efficacy of HBI-8000 administered twice a week (BIW) continuously Secondary: • • • To evaluate the safety and tolerability of HBI-8000 administered BIW continuously Endpoints: Primary: • Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: • • ORR by disease subtype (see inclusion criteria) • Median duration of progression-free survival (PFS) • Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, effica and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC HBI-8000 will be administered orally approximately 30 minutes after any regular meal. T treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days sole for the purpose to schedule assessments required by the study. <th>mie of Study.</th> <th colspan="5"></th>	mie of Study.						
Protocol No: HBI-8000-203 Study site(s): 25 to 35 sites in Japan and 10 to 15 sites in South Korea Study duration: Approximately 60 months Phase: 2b Planned study period: 4quarter 2016 (first patient in) to 3quarter 2018 (last patient in) 4quarter 2021 study completion Phase: 2b Objectives: Primary: • • To determine the efficacy of HBI-8000 administered twice a week (BIW) continuously Secondary: • • To evaluate the safety and tolerability of HBI-8000 administered BIW continuously Endpoints: Primary: • Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: • • ORR by disease subtype (see inclusion criteria) • Median duration of progression-free survival (PFS) • Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, effica and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC HBI-8000 will be administered orally approximately 30 minutes after any regular meal. T treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days sole for the purpose to schedule assessments required by the study.		•					
Study site(s): 25 to 35 sites in Japan and 10 to 15 sites in South Korea Study duration: Approximately 60 months Phase: 2b Planned study period: 4quarter 2016 (first patient in) to 3quarter 2018 (last patient in) 4quarter 2021 study completion Phase: 2b Objectives: Primary: • To determine the efficacy of HBI-8000 administered twice a week (BIW) continuously Secondary: • To evaluate the safety and tolerability of HBI-8000 administered BIW continuously Endpoints: Primary: • Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: • OBR by disease subtype (see inclusion criteria) • Median duration of progression-free survival (PFS) • Median duration of response (DOR) • Safety Exploratory: • Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, effica and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC HBI-8000 will be administered orally approximately 30 minutes after any regular meal. T treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days sole for the purpose to schedule assessments required by the study.	Protocol No:						
Study duration: Approximately 60 months Phase: 2b Planned study period: 4quarter 2016 (first patient in) to 3quarter 2018 (last patient in) 4quarter 2021 study completion Phase: 2b Objectives: Primary: • • To determine the efficacy of HBI-8000 administered twice a week (BIW) continuously Secondary: • • To evaluate the safety and tolerability of HBI-8000 administered BIW continuously Endpoints: Primary: • Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: • OBR by disease subtype (see inclusion criteria) • Median duration of progression-free survival (PFS) • Median duration of response (DOR) • Safety Exploratory: • Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficar and PK of HBI-8000 will be administered orally approximately 30 minutes after any regular meal. Threatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days sole for the purpose to schedule assessments required by the study.							
Planned study period: 4quarter 2016 (first patient in) to 3quarter 2018 (last patient in) 4quarter 2021 study completion Objectives: Primary: • To determine the efficacy of HBI-8000 administered twice a week (BIW) continuously Secondary: • To evaluate the safety and tolerability of HBI-8000 administered BIW continuously Endpoints: Primary: • Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: • ORR by disease subtype (see inclusion criteria) • Median duration of progression-free survival (PFS) • Median duration of response (DOR) • Safety Exploratory: • Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, effica and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC HBI-8000 will be administered orally approximately 30 minutes after any regular meal. T treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days sole for the purpose to schedule assessments required by the study.							
3quarter 2018 (last patient in) 4quarter 2021 study completion Objectives: Primary: • To determine the efficacy of HBI-8000 administered twice a week (BIW) continuously Secondary: • To evaluate the safety and tolerability of HBI-8000 administered BIW continuously Endpoints: Primary: • Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: • ORR by disease subtype (see inclusion criteria) • Median duration of progression-free survival (PFS) • Median duration of response (DOR) • Safety Exploratory: • Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, effica and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC HBI-8000 will be administered orally approximately 30 minutes after any regular meal. Theratment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days sole for the purpose to schedule assessments required by the study.							
 Objectives: Primary: To determine the efficacy of HBI-8000 administered twice a week (BIW) continuously Secondary: To evaluate the safety and tolerability of HBI-8000 administered BIW continuously Endpoints: Primary: Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: ORR by disease subtype (see inclusion criteria) Median duration of progression-free survival (PFS) Median duration of response (DOR) Safety Exploratory: Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficat and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC: HBI-8000 will be administered orally approximately 30 minutes after any regular meal. T treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days sole for the purpose to schedule assessments required by the study. 							
 Primary: To determine the efficacy of HBI-8000 administered twice a week (BIW) continuously Secondary: To evaluate the safety and tolerability of HBI-8000 administered BIW continuously Endpoints: Primary: Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: ORR by disease subtype (see inclusion criteria) Median duration of progression-free survival (PFS) Median duration of response (DOR) Safety Exploratory: Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficaa and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solution the purpose to schedule assessments required by the study. 		4quarter 2021 study completion					
 To determine the efficacy of HBI-8000 administered twice a week (BIW) continuously <u>Secondary:</u> To evaluate the safety and tolerability of HBI-8000 administered BIW continuously Endpoints: Primary: Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: ORR by disease subtype (see inclusion criteria) Median duration of progression-free survival (PFS) Median duration of response (DOR) Safety Exploratory: Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, effica and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days sole for the purpose to schedule assessments required by the study. 	Objectives:						
 Secondary: To evaluate the safety and tolerability of HBI-8000 administered BIW continuously Endpoints: Primary: Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: ORR by disease subtype (see inclusion criteria) Median duration of progression-free survival (PFS) Median duration of response (DOR) Safety Exploratory: Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficational PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC) HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solar for the purpose to schedule assessments required by the study. 	Primary:						
 To evaluate the safety and tolerability of HBI-8000 administered BIW continuously Endpoints: Primary: Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: ORR by disease subtype (see inclusion criteria) Median duration of progression-free survival (PFS) Median duration of response (DOR) Safety Exploratory: Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficate and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC): HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solve for the purpose to schedule assessments required by the study. 	• To determine	the efficacy of HBI-8000 administered twice a week (BIW) continuously					
 Endpoints: <u>Primary</u>: Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: ORR by disease subtype (see inclusion criteria) Median duration of progression-free survival (PFS) Median duration of response (DOR) Safety Exploratory: Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficaa and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC HBI-8000 will be administered orally approximately 30 minutes after any regular meal. T treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solar for the purpose to schedule assessments required by the study. 							
 Primary: Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: ORR by disease subtype (see inclusion criteria) Median duration of progression-free survival (PFS) Median duration of response (DOR) Safety Exploratory: Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficat and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC) HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solar for the purpose to schedule assessments required by the study. 		e safety and tolerability of HBI-8000 administered BIW continuously					
 Objective response rate (ORR; Complete Response [CR] + Partial Response [PR]) Secondary: ORR by disease subtype (see inclusion criteria) Median duration of progression-free survival (PFS) Median duration of response (DOR) Safety Exploratory: Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficaar and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC) HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solve for the purpose to schedule assessments required by the study. 	-						
 Secondary: ORR by disease subtype (see inclusion criteria) Median duration of progression-free survival (PFS) Median duration of response (DOR) Safety Exploratory: Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficational of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC) HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solve for the purpose to schedule assessments required by the study. 							
 ORR by disease subtype (see inclusion criteria) Median duration of progression-free survival (PFS) Median duration of response (DOR) Safety Exploratory: Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficat and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTCC HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solve for the purpose to schedule assessments required by the study. 	• •	oonse rate (ORR; Complete Response [CR] + Partial Response [PR])					
 Median duration of progression-free survival (PFS) Median duration of response (DOR) Safety Exploratory: Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficat and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC) HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solve for the purpose to schedule assessments required by the study. 							
 Median duration of response (DOR) Safety Exploratory: Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficat and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC) HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solve for the purpose to schedule assessments required by the study.	•						
 Safety Exploratory: Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficat and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC). HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solve for the purpose to schedule assessments required by the study.		1 0					
 Exploratory: Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficat and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC) HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solve for the purpose to schedule assessments required by the study. 		on of response (DOR)					
• Median duration of overall survival (OS) Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficat and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC) HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solve for the purpose to schedule assessments required by the study.	•						
Study Design: This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficat and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days sole for the purpose to schedule assessments required by the study.							
This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficat and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC). HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solve for the purpose to schedule assessments required by the study.	• Median duration of overall survival (OS)						
This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficat and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC). HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solve for the purpose to schedule assessments required by the study.	Study Design:						
and PK of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTC. HBI-8000 will be administered orally approximately 30 minutes after any regular meal. T treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days sole for the purpose to schedule assessments required by the study.		en-label non-randomized single arm study to evaluate the safety efficacy					
HBI-8000 will be administered orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days solve for the purpose to schedule assessments required by the study.							
treatment will be continuous, with 3-4 days between dosing. A cycle is defined as 28 days sole for the purpose to schedule assessments required by the study.							
for the purpose to schedule assessments required by the study.							
	for the purpose to sen	duie assessments required by the study.					
Treatment-related adverse events (AEs) will be graded according to National Cancer Institute	Treatment-related adv	erse events (AEs) will be graded according to National Cancer Institute					
Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. In the event of							
unacceptable toxicities, study drug will be held until recovery and dosing will be resumed at							
reduced dose level, following protocol guidelines. An unacceptable toxicity is defined as the							
following:							
-	-						
• Grade 4 afebrile neutropenia > 7 days despite optimal growth factor support	• Grade 4 afebr	ile neutropenia > 7 days despite optimal growth factor support					
• Grade \geq 3 febrile neutropenia or neutropenic infection							
• Grade \geq 3 thrombocytopenia with clinically significant bleeding or Grade \geq							
thrombocytopenia requiring a platelet transfusion	• Grade ≥ 3						

- Grade ≥3 nausea, vomiting, diarrhea, or electrolyte imbalances lasting greater than 48 hours despite optimal prophylactic and curative treatment
- Grade \geq 3 allergic reaction
- Grade \geq 3 other non-hematologic AEs
- Treatment delay >14 days secondary to recovery from study drugs- related AEs

For determination of efficacy, HBI-8000 administration will be continued until disease progression (PD) or unacceptable toxicities are observed despite appropriate dose reduction or treatment interruption.

=	40 patients evaluable for efficacy with approximately 27 from Japan and				
	13 from Korea. To ensure meeting this target, an estimated 50 to				
	60 patients would be enrolled in anticipation that some patients may not				
	complete study treatment.				
Entry	Inclusion				
Entry Criteria:	 Inclusion Histological or cytological diagnosis of the following peripheral T-cell lymphoma (PTCL) subtypes as defined by the WHO classification (2008) may be included: PTCL, NOS Angioimmunoblastic T-cell lymphoma (AITL) Anaplastic large-cell lymphoma (ALCL), ALK⁺ Anaplastic large-cell lymphoma (ALCL), ALK⁻ Enteropathy-associated T-cell lymphoma (EATL) Hepatosplenic T-cell lymphoma Patients for whom at least 1 measurable lesion is confirmed by the lesion assessment at baseline; An evaluable lesion is defined according to Cheson criteria 2014. Relapsed or refractory disease after receiving ≥1 prior systemic therapy with anti-tumor agent(s) and there is no other standard treatment which can be considered appropriate for patients. Systemic therapy is defined as frontline chemotherapy or immunotherapy administered systemically. Male or female, age 20 years or older Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 Life expectancy of greater than 3 months Meeting the following baseline laboratory criteria for screening: Absolute Neutrophil Count >1500/µL independent of growth factor support within 7 days Platelets >75,000/µL independent of transfusion within 14 days Serum aspartate aminotransferase/glutamyl oxaloacetic transaminase (AST/SGOT) and alanine 				
	aminotransferase/glutamyl pyruvic transaminase (ALT/SGPT) $\leq 3 \times ULN$				
	f. Serum Bilirubin $\leq 1.5 \times ULN$				
	 Setum Binution S 1.5 × OLN Negative serum pregnancy test for females of childbearing (reproductive) potential. Female patients of child bearing potential must use an effective method of birth control (e.g., hormonal 				

9.	 contraceptive, intrauterine device, diaphragm with spermicide or condom with spermicide) during treatment period and 1 month thereafter. Males must use an effective method of birth control (2 barrier methods) during treatment period and 3 months thereafter. Note: Female patients will be considered to be women of childbearing potential unless having undergone permanent contraception or postmenopausal. Postmenopausal is defined as at least 12 months without menses with no other medical reasons (e.g., chemical menopause because of treatment with antimalignant tumor agents) Signed informed consent
1. 2. 3.	Patients in whom central nervous system lymphoma is recognized during screening (if suspected clinically, imaging study should be performed to confirm) Male patients with QTcF >450 msec at screening, female patients with QTcF >470 msec at screening or patients with congenital long QT syndrome, clinically significant arrhythmia, history of congestive heart failure (New York Heart Association Class III or IV) or acute myocardial infarction within 6 months of starting the study drug Patients with known hypersensitivity to benzamide class of compounds or any of the components of HBI-8000 tablets, and patients with prior exposure of HBI-8000 Patients with a history of second malignancy other than disease under study. The exceptions are diseases (excluding diseases listed below) that have been treated with curative intent with no evidence of recurrence in past 5 years. Furthermore, if the second malignancy is one of the following diseases that were treated with curative intent, it is only required that there is no evidence of recurrence in past 2 year. a. Basal cell carcinoma of the skin b. Squamous cell carcinoma of the skin
	 c. Cervical carcinoma in situ d. Carcinoma in situ of the breast e. An incidental histological finding of prostate carcinoma (TNM stage T1a or T1b) f. Early-stage gastric cancer treated with endoscopic mucosal
	resection or endoscopic submucosal dissection g. Thyroid cancer with differentiated histology (e.g. papillary)
5.	treated with curative intent Autologous stem cell transplantation within 12 weeks (84 days) of starting the study drug
6.	History of allogeneic stem cell transplantation
	Organ transplantation recipients except for autologous hematopoietic stem cell transplantation
8.	Uncontrolled inter-current infection
9.	Hepatitis B surface antigen-positive, or hepatitis C virus antibody positive. In case hepatitis B core antibody and/or hepatitis B surface antibody is positive even if hepatitis B surface antigen-negative, a hepatitis B virus DNA test (real-time polymerase chain reaction
	repaires 2 mus 2111 test from time polymetuse chain reaction

	(PCR) measurement) should be performed and if positive, the patient
	should be excluded from study
	10. Any history of testing positive for human immunodeficiency virus
	(HIV) or known acquired immunodeficiency syndrome (AIDS)
	11. Uncontrolled diabetes mellitus, hypertension, endocrine disorder,
	bleeding disorder
	12. Major surgery or radiation therapy within 28 days of starting the study
	drug
	13. Receiving investigational agents or anti-cancer therapy, within 28
	days, nitrosourea or mitomycin C within 42 days of starting the study
	drug
	14. Receiving antibody therapy for PTCL within 12 weeks of starting
	· · · ·
	the study drug
	15. Women who are breastfeeding or women who are not willing to stop
	breastfeeding during study treatment period and for 30 days after the
	last dose of study drug
	16. Potential for non-compliance or at increased risk based on
	investigator's judgement
Excluded Prior or	The following drugs are prohibited.
Concomitant	Drugs known to produce significant QT prolongation and
Medications or	ventricular dysrhythmias
Therapy:	Prohibited from signing informed consent through the EoT
	assessment
	• Anti-cancer therapy other than study medication
	Prohibited during the study and within the following time intervals
	prior to the first dose of study drug.
	- 4 weeks for anti-cancer chemotherapy
	 6 weeks for nitrosourea and mitomycin C
	 12 weeks for anti-cancer monoclonal antibody therapy
	Corticosteroid prescribed for medical conditions other than lymphoma is
	not considered as an anti-cancer therapy for this study, for example:
T	chronic obstructive pulmonary disease, allergy, topical steroids for rash.
Treatments:	Study drug is to be taken after any regular meal twice weekly, each dose
	separated by 3-4 days. Treatment will continue until PD in the absence
T 60 1 D 4	of unacceptable toxicity.
Efficacy Data:	Response and progression for PTCL will be evaluated according to the
	revised criteria for response assessment in lymphoma [Cheson 2014]. To
	be included in final efficacy analyses, the histopathology diagnosis of
	disease will be verified by Central Pathology Review, and disease
	response will be confirmed by Independent Radiology and Independent
	Overall Efficacy Review.
Safety Data:	All patients who receive at least one dose of HBI-8000 will be evaluable
	for safety. Adverse event severity (grade) will be defined according to
	Common Terminology Criteria for Adverse Events (CTCAE) Version
	4.03. Serial ECGs and clinical laboratory tests will be collected to
	evaluate safety and potential toxicity. Laboratory and other tests, as
	appropriate to the clinical situation, may be obtained more frequently than
	stipulated in the schedules of events.
	All reported AEs will be collected, evaluated and coded using Medical
	Dictionary for Regulatory Activities (MedDRA).

Statistical Procedures:

Statistical analysis for all safety and efficacy will be primarily descriptive in nature. Categorical variables will be summarized by frequency distributions (number and percentages of patients), continuous variables will be summarized by mean, standard deviation, median, minimum, maximum, and time-to-event variables will be summarized using Kaplan-Meier methods and figures for the estimated median time. A formal statistical analysis plan will be completed prior to database lock and any study-related analyses.

Disease diagnosis including histological subtypes will be confirmed by central pathology review conducted by independent pathologists.

Efficacy should be analyzed using Full analysis set (FAS) and Per protocol set (PPS).

The FAS is defined as Patients meeting all eligibility criteria and having received at least one dose of study medication, and at least one efficacy assessment of disease with either imaging studies or clinical examination after receiving study medication.

The PPS is defined as Patients meeting all eligibility criteria and having completed Cycle 1 treatment or discontinued study treatment during cycle 1 due to clinical PD. It should be noted that the PPS includes subjects who discontinue within Cycle 1 due to clinical PD without imaging studies to assess disease status.


In addition, Patients who are assessed as Non-PTCL by the central pathology review committee should be excluded from the FAS and PPS for efficacy. The non-PTCL subjects will be included in safety analysis for the study.

The primary efficacy analysis is conducted in the PPS. The Efficacy analysis using the FAS will be also reported.

It is estimated that 40 evaluable patients are adequate to provide efficacy assessment. Assuming a 30% ORR in this population of 40 evaluable patients, the conclusion would be that there is a 95% chance that the ORR in this protocol population would lie between 15.8% and 44.2%. The power for showing the response rate >10% at 5% two-sided alpha in 40 patients is 89%.

All patients who have received any amount of study medication will be considered as evaluable for safety. Safety data will be summarized with descriptive statistics and frequency tables and will include AEs, hematology, coagulation, serum chemistry, urinalysis, vital signs, and ECG data. Laboratory values will be summarized by numerical value and toxicity grade.

Supplemental Figure Figure S1. Disposition of patients



SAF: safety analysis set FAS: full analysis set PPS: per protocol set

Figure S2. Forest Plot of Objective Response Rate by Subgroup

Subgroup	n	ORR	ORR (95% CI)
Overall:	46		0.457 (0.309, 0.610)
PTCL subtype at screening:		Ĭ	
PTCL-NOS	34	_	0.353 (0.197, 0.535)
AITL	8		• 0.875 (0.473, 0.997)
ALCL, ALK-	3 —	• • •	0.333 (0.008, 0.906)
EATL	1 —		→ 1.000 (0.025, 1.000)
Country:			
Japan	34	_	0.529 (0.351, 0.702)
Korea	12 —		0.250 (0.055, 0.572)
Sex:			
Male	31	\	0.484 (0.302, 0.669)
Female	15	•	0.400 (0.163, 0.677)
Age (years):			
<65	13		0.538 (0.251, 0.808)
>=65 to <75	19	_	0.526 (0.289, 0.756)
>=75	14 -	→	0.286 (0.084, 0.581)
Number of regimens before the study	treatment:		
Less than 3 regimens	29		0.586 (0.389, 0.765)
3 or more regimens	17 —		0.235 (0.068, 0.499)
Days from end of the last previous trea	atment:		
< 3 months	20	_	0.350 (0.154, 0.592)
>=3 months	26	_	0.538 (0.334, 0.734)
Refractory or relapsed PTCL:			
Refractory	18	—	0.333 (0.133, 0.590)
Relapsed	28		0.536 (0.339, 0.725)
ECOG Performance Status:			
0	24	\	0.500 (0.291, 0.709)
1	21		0.429 (0.218, 0.660)
2	1 ⊷		0.000 (0.000, 0.975)
	0.00	0.25 0.50 0.75	1.00

Supplemental Table Table S1. Prior romidepsin treated patients summary

Case	Age	Subtype	N of prior systemic therapies	Autologous stem-cell transplantation	romidepsin treated line	Overall response of romidepsin	Overall response of tucidinostat
1	68	PTCL-NOS	4	No	2	CR	PR
2	65	AITL	3	No	2	CRu	SD, excluded from the PPS
3	78	PTCL-NOS	4	No	2	CR	SD
4	78	PTCL-NOS	5	No	4	PR	PD

N = number,

CR = complete response, CRu = complete response/unconfirmed, PD = progressive disease, PR = partial response, SD = stable disease,

AITL = angioimmunoblastic T-cell lymphoma, PTCL-NOS = peripheral T-cell lymphoma, not otherwise specified,

PPS = per-protocol set